AIM
RLAY icon

Aigen Investment Management’s Relay Therapeutics RLAY Stock Holding History

Aigen Investment Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-22,075
Closed -$220K – 757
2026
Q1 		$220K Buy
+22,075
New +$197K 0.06% 409
2023
Q4 		– Sell
-16,828
Closed -$142K – 1035
2023
Q3 		$142K Buy
+16,828
New +$181K 0.03% 716
2021
Q4 		– Sell
-7,328
Closed -$231K – 1159
2021
Q3 		$231K Buy
+7,328
New +$247K 0.04% 391

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Aigen Investment Management's RLAY Position: Q2 2026 in Review

Aigen Investment Management sold out of Relay Therapeutics (RLAY) in Q2 2026, closing a stake of 22,075 shares — an estimated $220K sold.

Aigen Investment Management first reported a position in RLAY in Q3 2021 and held it in 3 quarters. The position peaked at $231K in Q3 2021. 260 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Aigen Investment Management reported no remaining Relay Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Aigen Investment Management sold 22,075 Relay Therapeutics shares in Q2 2026, an estimated $220K.
  • Aigen Investment Management first reported a position in Relay Therapeutics in Q3 2021 and held it in 3 quarters.
  • Aigen Investment Management's Relay Therapeutics position peaked at $231K in Q3 2021.
  • 260 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.